New and updated clinical data presented by biopharma firms at the European Society for Medical Oncology (ESMO) Congress, including: Agenus, Anheart, Apollomics, Artios, Arvinas, Ascentage, Astellas, Astrazeneca, Ayala, Bicara, Cantargia, CDR-Life, Cel-Sci, Daiichi, Dizal, Elucida, Eli Lilly, Exelixis, Galecto, Genentech, Harpoon, Hookipa, Hummingbird, Ideaya, Immuneoncia, Immunocore, Inspirna, IO Biotech, Janssen, Kazia, Lytix, Medigene, Merck & Co., Merus, Nanobiotix, Oncolytics, Oric, PDS, Regeneron, Revolution, Ryvu, Seagen, Sutro, Theriva, Transcenta, Ultimovacs.